GlassScriptPhysician profile
Matthew Thompson
NPI 1639175441
$2,028.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $43.94 · 2021: $250 · 2022: $230 · 2023: $338 · 2024: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $741.04 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $631.64 | 2019-2024 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $274.34 | 2019-2024 | |
| Genzyme Corporation | $245.66 | 2021-2024 | |
| Janssen Biotech, INC. | $188.44 | 2019-2024 | Tremfya |
| Pfizer INC. | $182.49 | 2019-2020 | |
| Genentech USA, INC. | $128.13 | 2019-2022 | |
| Amgen INC. | $72.50 | 2019-2023 | Otezla |
| Galderma Laboratories, L.P. | $70.52 | 2019-2022 | |
| Ucb, INC. | $55.44 | 2023-2024 | Bimzelx, Cimzia |
| Celgene Corporation | $44.52 | 2019 | |
| Sun Pharmaceutical Industries INC. | $34.54 | 2021-2024 | |
| Nobel Biocare USA | $31.98 | 2021 | |
| Incyte Corporation | $31.41 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $19.92 | 2019 | |
| Lilly USA, LLC | $17.04 | 2023 | Taltz, Olumiant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.